Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961632 | 0.81 | CES2 (0.65) | ABCG2ALDH1A1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL8780285 | 0.81 | ABCG2 (0.59) | ABCG2ALDH1A1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL30495847 | 0.80 | ABCG2 (0.39) | ABCG2ALDH1A1KDM4EGAAMEN1 | |
| Water SCHEMBL8628497 | 0.79 | ABCG2 (0.58) | ABCG2ALDH1A1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL546672 | 0.79 | F3 (0.59) | ALDH1A1CYP1B1CYP1A2MEN1MAPT | |
| Water SCHEMBL8629577 | 0.79 | ABCG2 (0.58) | ABCG2ALDH1A1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL25508540 | 0.77 | CES2 (0.64) | ABCG2ALDH1A1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL16953789 | 0.77 | ALDH1A1 (0.48) | ABCG2ALDH1A1CYP1A1CYP1B1KDM4E | |
| SCHEMBL28393758 | 0.77 | ALDH1A1 (0.48) | ABCG2ALDH1A1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL6350350 | 0.76 | ABCG2 (0.60) | ABCG2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2721014-A2 | HYBRID MOLECULES CONTAINING PHARMACOPHORES OF FLUCONAZOLE AS ANTIFUNGAL AGENTS AND THEIR PREPARATION | FDC Limited (IN) | 2014-04-23 | — | — | EP | disclosed |
| US-20130287789-A1 | Organic Compounds | NOVARTIS AG (CH) | 2013-10-31 | — | — | US | disclosed |
| WO-2012172562-A2 | HYBRID MOLECULES CONTAINING PHARMACOPHORES OF FLUCONAZOLE AS ANTIFUNGAL AGENTS AND THEIR PREPARATION | FDC LIMITED (IN) | 2012-12-20 | — | — | WO | disclosed |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2005-09-15 | — | — | US | disclosed |
| CN-1612856-A | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof | AVENTIS PHARMA SA (FR) | 2005-05-04 | — | — | CN | disclosed |
| EP-1453790-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2003-08-14 | — | — | US | disclosed |
| WO-2003048106-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287789-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | ABCG2 3110/4885ALDH1A1 304/4885CYP1A1 159/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | ABCG2 3110/4885ALDH1A1 304/4885CYP1A1 159/4885 |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | ABCG2 3826/4885ALDH1A1 161/4885CYP1A1 24/4885 |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | ABCG2 3826/4885ALDH1A1 161/4885CYP1A1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.